Destiny Pharma PLC’s (AIM:DEST) chief executive Neil Clark joined Proactive after the release of interim results that showed it had made impressive clinical progress with its next-generation antibiotics.
The group is now looking for licensing partners for its phase III-ready asset NTCD-M3. Clark talked to Chris Rhodes about NTCD-M3 and the company’s XF-73 nasal gel.
#destinypharma #aim #lse #healthcare #antibiotics
